CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Based Regimens
Helen P. Kourea, Foteinos-Ioannis Dimitrakopoulos, Georgia-Angeliki Koliou, Anna Batistatou, Kyriaki Papadopoulou, Mattheos Bobos, Anthoula Asimaki-Vlachopoulou, Sofia Chrisafi, Kitty Pavlakis, Kyriakos Chatzopoulos, Eleni Galani, George Pentheroudakis, Dimitrios Pectasides, Dimitrios Bafaloukos, Eleni Res, Pavlos Papakostas, Angelos Koutras, Vassiliki Kotoula, George Fountzilas
Cancer Research and Treatment. 2022;54(4):1053-1064.   Published online 2021 November 17    DOI: https://doi.org/10.4143/crt.2021.748

Excel Download

Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Based Regimens
Cancer Research and Treatment. 2022;54(4):1053-1064   Crossref logo
Link1 Link2 Link3

Trastuzumab Regimens for HER2-Overexpressing Metastatic Breast Cancer
Clinical Breast Cancer. 2003;4(5):329-337   Crossref logo
Link1 Link2

HER2-Overexpressing Metastatic Breast Cancer: The Role of Trastuzumab Regimens
Clinical Breast Cancer. 2003;4(5):338-339   Crossref logo
Link1 Link2

Cardiac Toxicity of Trastuzumab-Related Regimens in HER2-Overexpressing Breast Cancer
Clinical Breast Cancer. 2007;7(8):22-29   Crossref logo
Link1 Link2

Phase II Trial of Gemcitabine plus Trastuzumab in Metastatic Breast Cancer Patients Previously Treated with Chemotherapy: Preliminary Results
Clinical Breast Cancer. 2002;3:S17-S20   Crossref logo
Link1 Link2

Retraction Note: Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
British Journal of Cancer. 2014;110(12):2996-2996   Crossref logo
Link1 Link2 Link3

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
British Journal of Cancer. 2014;110(8):1968-1976   Crossref logo
Link1 Link2 Link3

Effect of Trastuzumab on Health-Related Quality of Life in Patients With HER2-Positive Metastatic Breast Cancer: Data From Three Clinical Trials
Clinical Breast Cancer. 2010;10(4):288-293   Crossref logo
Link1 Link2

Cochrane review - Trastuzumab-containing regimens for metastatic breast cancer
Journal of Evidence-Based Medicine. 2014;7(3):229-229   Crossref logo
Link1 Link2 Link3

Body mass index and clinical outcomes in trastuzumab-treated metastatic breast cancer patients: An alternative explanation for the lack of association
The Breast. 2018;39:150-151   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.